Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Hewlett Packard Enterprise Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Hewlett Packard Enterprise Co trades at $49.98 (market cap $65.63B). The key difference: Hewlett Packard Enterprise Co is far larger — about 8.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Hewlett Packard Enterprise Co pays a 1.15% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | HPE | |
|---|---|---|
Market Cap | $8.04B | $65.63B |
Sector | Health | Technology |
52-Week High | $339.75 | $56.14 |
52-Week Low | $241.71 | $19.81 |
Enterprise Value | $7.85B | $81.58B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
HPE trades at $47.24, down 2.61% on the day, with a bullish technical signal from moving averages. Recent earnings beats and a consensus price target of $69.69 suggest upside potential. The company reported revenue of $34.30B in 2025, though net income fell sharply to $57M. Strong AI infrastructure demand and a nearly $6B backlog, as noted by The Motley Fool on July 9, 2026, highlight growth catalysts.
Outlook is positive with AI-driven demand boosting revenue projections to $38.8B in 2026. Risks include high debt-to-asset ratio of 29.48% in 2025 and margin pressures. Analysts are mixed with 46% buy ratings, indicating cautious optimism for long-term investors amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
